EUVIMEDEUVIMED entdecken
Crossref

Clinical and genomic convergence of high-risk CCUS and lower-risk myelodysplastic syndromes/neoplasms

Zhuoer Xie iD, Zena Komrokji iD, Michael Otterstatter iD, Ling Zhang iD, Lynn Moscinski iD, Najla Al Ali, David Sallman iD, Jeffrey Lancet, Gregory A Abel, Robert C Lindsley, Rafael Bejar iD, Matthew Walter und 5 weitere

Blood · 12.11.2026 · 148 (20) · 2528-2539

DOI: 10.1182/blood.2026033085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, erschienen am 12.11.2026. Verfasst von Zhuoer Xie und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clonal cytopenia of undetermined significance (CCUS) is defined by unexplained cytopenias with myeloid-associated somatic mutations not meeting the diagnostic criteria for myelodysplastic syndromes/neoplasms (MDS), yet it carries a highly risk-stratified probability of progression to myeloid neoplasms. The clinical distinction between CCUS and lower-risk MDS (LR-MDS) is challenging because current criteria rely heavily on semiquantitative morphologic thresholds, despite substantial clinical and molecular overlap. In this prospective study of 409 patients with CCUS and 241 with LR-MDS, we applied harmonized diagnostic and progression criteria, rigorous centralized pathology review, and uniform genomic profiling to compare clinical, molecular, and outcome data. Risk stratification was performed using 2 independent models: the clonal hematopoiesis risk score (CHRS) and the clonal cytopenia risk score (CCRS). Patients with high-risk CCUS, as defined by CHRS or CCRS, exhibited clinical features and event rates comparable to those with LR-MDS. In contrast, patients with low- or intermediate-risk CCUS had markedly improved outcomes, supporting conservative management. These findings underscore that CHRS and CCRS are clinically informative tools that extend beyond morphology-based classification and enable a risk-adapted approach to the management of CCUS. Importantly, a subset of patients with high-risk CCUS demonstrated substantial clinical and genomic convergence with LR-MDS, supporting their consideration for enrollment in prospective clinical trials designed for LR-MDS. These observations highlight the need for further study of risk-adapted therapeutic approaches in this population and underscore the importance of prospective clinical evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesHumansCytopeniaFemaleMaleClonal HematopoiesisAgedAged, 80 and overProspective StudiesMiddle AgedGenomicsRisk Factors

Autor:innen und Institutionen

  • Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.
  • The Emmes Company LLC, Rockville, MD.
  • Department of Hematopathology and Laboratory Medicine, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
  • Division of Hematologic Malignancies and Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Division of Hematology and Cellular Therapy, University of California San Diego, San Diego, CA.

ORCID-Profile: Zhuoer Xie, Zena Komrokji, Michael Otterstatter, Ling Zhang, Lynn Moscinski, David Sallman, Rafael Bejar, Mikkael A Sekeres, Rami Komrokji, Nancy Gillis

Zitieren

APA

Xie, Z., Komrokji, Z., Otterstatter, M., Zhang, L., Moscinski, L., Al Ali, N., Sallman, D., Lancet, J., Abel, G. A., Lindsley, R. C., Bejar, R., Walter, M., Dezern, A., Sekeres, M. A., Komrokji, R., Gillis, N., & Padron, E. (2026). Clinical and genomic convergence of high-risk CCUS and lower-risk myelodysplastic syndromes/neoplasms. Blood, 148(20), 2528-2539. https://doi.org/10.1182/blood.2026033085

Vancouver

Xie Z, Komrokji Z, Otterstatter M, Zhang L, Moscinski L, Al Ali N, et al. Clinical and genomic convergence of high-risk CCUS and lower-risk myelodysplastic syndromes/neoplasms. Blood. 2026;148(20):2528-2539. doi:10.1182/blood.2026033085

BibTeX
@article{Xie2026,
  author = {Xie, Zhuoer and Komrokji, Zena and Otterstatter, Michael and Zhang, Ling and Moscinski, Lynn and Al Ali, Najla and Sallman, David and Lancet, Jeffrey and Abel, Gregory A and Lindsley, Robert C and Bejar, Rafael and Walter, Matthew and Dezern, Amy and Sekeres, Mikkael A and Komrokji, Rami and Gillis, Nancy and Padron, Eric},
  title = {Clinical and genomic convergence of high-risk CCUS and lower-risk myelodysplastic syndromes/neoplasms},
  journal = {Blood},
  year = {2026},
  volume = {148},
  number = {20},
  pages = {2528--2539},
  doi = {10.1182/blood.2026033085}
}
Kostenlos starten →